PATHFINDER 2: a Multi-Cancer Early Detection Study

Exclusion Criteria

• •1. Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
• •2. Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated.
• •* Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
• •3. Prior/Concurrent Concomitant Therapy (Medications/Treatments):
• •* Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date. Adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer) is not an exclusion criterion.
• •4. Individuals who will not be able to comply with the protocol procedures.
• •5. Individuals who are not currently registered patients at a participating center.
• •6. Previous or current participation in another GRAIL-sponsored study. "Participation" is defined as having signed consent and provided a blood sample.
• •7. Previous or current employees or contractors of GRAIL.
• •8. Current pregnancy (by self-report of pregnancy status)